Pharmaceutical - USA, Nephrology and Hepatology

Filter

Popular Filters

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

29-09-2014

Achillion Pharmaceuticals is in a prime position to develop its own all-oral hepatitis C treatment as…

Achillion PharmaceuticalsFinancialMarkets & MarketingNephrology and HepatologyPharmaceuticalUSA

OPKO's second Rayaldee Ph III trial meets primary endpoints

OPKO's second Rayaldee Ph III trial meets primary endpoints

24-09-2014

US drugmaker OPKO Health has released successful top-line results from the second and final pivotal Phase…

Nephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeResearchUSA

Keryx' shares fall as FDA approves kidney drug, but with warnings

Keryx' shares fall as FDA approves kidney drug, but with warnings

07-09-2014

US drugmaker Keryx Biopharmaceuticals has received approval from the US Food and Drug Administration…

ferric citrateKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenvelaSanofiUSAZerenex

Intercept shares rocket on positive liver drug results

Intercept shares rocket on positive liver drug results

12-08-2014

Shares of US drug developer Intercept Pharmaceuticals leapt 53% to $358.07 in after-hours trading on…

Intercept PharmaceuticalsLiver diseaseNephrology and Hepatologyobeticholic acidPharmaceuticalResearchUSA

OPKO’s Rayaldee Ph III trial meets primary endpoints in SHPT

12-08-2014

US drugmaker OPKO Health has released positive top-line results from the first pivotal Phase III trial…

Endocrine systemJoel MelnickNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeResearchUSAVitamin D

Tesamorelin, which reduces abdominal fat in HIV patients, may also reduce fat in liver

22-07-2014

The only drug to receive US Food and Drug Administration approval for reduction of the abdominal fat…

EgriftaEMD SeronoMerck KGaANephrology and HepatologyPharmaceuticalResearchtesamorelinTherapy for HIVUSA

Amgen announces positive Phase III results for AMG 416 in kidney disease

Amgen announces positive Phase III results for AMG 416 in kidney disease

18-07-2014

USA-based Amgen, the world's leading independent biotech firm, has said its Phase III study evaluating…

AMG 416AmgenChronic kidney diseaseHyperparathyroidismNephrology and HepatologyPharmaceuticalResearchSecondary hyperparathyroidismUSA

US nephrologists view hyperphosphatemia treatment

US nephrologists view hyperphosphatemia treatment

11-07-2014

Surveyed nephrologists report awareness of the US Food and Drug Administration's approval of Vifor Fresenius…

AmgenFreseniusGlaxoSmithKlineLa Jolla PharmaceuticalMarkets & MarketingNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeSensiparUSAvelcalcetideVelphoroVenoferVifor Pharma

Retrophin acquires US Thiola rights from Mission Pharmacal

Retrophin acquires US Thiola rights from Mission Pharmacal

30-05-2014

US drugmaker Retrophin has entered into a license agreement with Mission Pharmacal, a private company…

LicensingMission PharmacalNephrology and HepatologyPharmaceuticalRare diseasesRetrophinThiolaUSA

La Jolla’s shares soar as it reports positive results in kidney disease trial

12-03-2014

US-based La Jolla Pharmaceutical Company has announced positive top-line results from its randomized,…

La Jolla PharmaceuticalNephrology and HepatologyPharmaceuticalResearchUSA

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Velphoro receives US FDA approval for hyperphosphatemia in CKD

Velphoro receives US FDA approval for hyperphosphatemia in CKD

28-11-2013

Switzerland-based Vifor Pharma has received US Food and Drug Administration approval for Velphoro for…

Nephrology and HepatologyPharmaceuticalRegulationUSAVelphoroVifor Pharma

Chronic kidney disease market to witness slight decline by 2017

Chronic kidney disease market to witness slight decline by 2017

12-11-2013

The value of the chronic kidney disease market could drop 2.5% between 2012 and 2017 due to the loss…

EuropeFinancialGenzymeMarkets & MarketingNephrology and HepatologyPharmaceuticalRenagelRenvelaUSAZemplar Capsules

Back to top